학술논문
2020台灣腦中風學會非心因性缺血性腦中風抗血小板藥物治療指引 / 2020 Taiwan Stroke Society Guideline on Antiplatelet Therapy for Noncardioembolic Ischemic Stroke
Document Type
Article
Author
陳柏霖 / Po-Lin Chen; 陳志昊 / Chih-Hao Chen; 湯頌君 / Sung-Chun Tang; 連立明 / Li-Ming Lien; 張谷州 / Ku-Chou Chang; 李俊泰 / Jiunn-Tay Lee; 劉崇祥 / Chung-Hsiang Liu; 陳右緯 / Yu-Wei Chen; 陳龍 / Lung Chan; 林雅如 / Ya-Ju Lin; 宋碧珊 / Pi-Shan Sung; 謝鎮陽 / Sheng-Yang Hsieh; 鍾芷萍 / Chih-Ping Chung; 鄭建興 / Jiann-Shing Jeng; 非心因性缺血性腦中風抗血小板藥物治療指引共識小組 / Taiwan Stroke Society Guideline Consensus Group
Source
台灣中風醫誌 / Formosan Stroke Journal. Vol. 2 Issue 1, p5-34. 30 p.
Subject
Language
繁體中文
ISSN
2664-1976
Abstract
In the past 7 years, several important antiplatelet trials have been completed with pivotal findings. These results were significant and have been already changing the daily practice of treatment for ischemic stroke (IS). One of the most important findings is the concept of dual antiplatelet therapy for acute noncardioembolic IS or transient ischemic attack. The timing and duration of antiplatelet therapy also have significant impact on the outcomes of IS. In addition to traditional antiplatelets, such as aspirin or clopidogrel, other antiplatelets, including cilostazol, ticagrelor, and prasugrel have also been investigated for the efficacy and safety in the treatment for IS. Another important issue is the use of antiplatelet therapy in primary prevention of cerebro- and cardio-vascular events, the results of several large clinical trials have shown the antiplatelet therapy in specific populations with various estimated risks. The purpose of this current guideline is to update the 2016 Taiwan Stroke Society (TSS) Guideline on Antiplatelet Therapy for Noncardioembolic Ischemic Stroke particularly in areas for which new evidence has emerged since its publication. The TSS Guideline Consensus Group revised the guideline based on the data of several studies which are important and influential. This guideline focuses on three major topics, including secondary prevention, acute management, and primary prevention for noncardioembolic ischemic stroke. Recommendations and reviews of the evidences are provided.